VYRE Network Partners with Recurrent Ventures to launch “We Are The Mighty”, a Military Lifestyle Focused Channel
19 mars 2024 08h22 HE
|
VYRE Network
VYRE Network, is pleased to announce its partnership with Recurrent Ventures to create, curate and distribute military lifestyle video content.
Black Book Enhances EV Values with Recurrent Battery Insights
23 janv. 2024 09h00 HE
|
Recurrent Auto; Black Book
LAWRENCEVILLE, Ga., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Black Book today introduced the industry's first electric vehicle (EV) valuations, dubbed Battery Adjusted Values™, which incorporate battery...
Recurrent Shows EV Prices Soared in 2021, Benefitting Tesla the Most
10 janv. 2022 10h30 HE
|
Recurrent Auto
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s leading analyst of electric vehicle (EV) battery health, today released its Q1 2022 Used Electric Car Buying Report. Most...
Data From Recurrent Shows the Substantial Impact Winter Weather Has on EV Batteries
14 déc. 2021 10h30 HE
|
Recurrent Auto
SEATTLE, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s leading analyst of electric vehicle (EV) battery health, today released new winter range data on the impact that freezing...
Data From Recurrent Reveals 30% of Owners of Recalled Chevy Bolts Are Not Following General Motors Recall Guidelines for Vehicle Charging
25 août 2021 12h00 HE
|
Recurrent Auto
SEATTLE, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s only analyst of electric vehicle (EV) battery health, today released new data analyzing the actions of more than 1,000 Chevy...
Recurrent Introduces New Guides Analyzing Battery Range on Specific Makes and Models of Pre-Owned Electric Vehicles
13 juil. 2021 11h01 HE
|
Recurrent Auto
SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s analyst of electric vehicle battery health, today announces the release of the first-ever electric vehicle battery guides for...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
29 juil. 2019 08h00 HE
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...